CHRO

Channel Therapeutics Corporation · AMEX

Sector Health Technology
Industry Biotechnology
Website chromocell.com
Employees(FY) 3
ISIN US1711261057

Performance

-6.6%

+18.95%

-26.11%

-54.68%

-86.59%

YTD

-86.59%

Profile

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Advanced Technical Analysis

Technical Analysis of CHRO 2024-12-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 26 and the Technical Score at 33, both indicating weakness, while the Oscillators Score at 40 suggests a neutral stance. This combination implies a lack of strong bullish momentum, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CHRO

Stock Rank

Recent News & Updates

2024-12-19 20:00
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine(Globenewswire)
2024-12-17 19:30
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model(Globenewswire)
2024-11-20 20:49
Chromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program Updates(Globenewswire)
2024-10-28 20:30
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain(Globenewswire)
2024-10-27 20:00
Chromocell to Present at Upcoming Fall Investor Conferences(Globenewswire)
2024-10-23 20:45
Chromocell Announces Amendment to Stock Repurchase Plan(Globenewswire)
2024-09-19 20:35
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing(Yahoo Finance)
2024-09-16 00:07
Life Sciences Virtual Investor Forum Agenda Announced for September 19th(Yahoo Finance)
2024-09-15 20:35
Chromocell to Participate in Life Sciences Investor Forum September 19th(Yahoo Finance)
2024-09-02 21:00
Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-06 20:45
Chromocell Announces Stock Repurchase Plan(Globenewswire)
2024-07-14 21:00
Chromocell to Participate in the Virtual Investor Lunch Break Series(Globenewswire)
2024-05-12 21:00
Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024(Globenewswire)
2024-04-08 20:30
Chromocell Issues Letter to Stockholders from Chief Executive Officer(Globenewswire)
2024-03-20 20:30
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler(Globenewswire)
2024-03-17 22:00
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023(Yahoo Finance)
2024-03-11 22:30
Sidoti Events, LLC's Virtual March Small-Cap Conference(Accesswire)
2024-03-10 21:00
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14(Yahoo Finance)
2024-02-26 19:00
Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions(Yahoo Finance)
2024-02-21 03:47
Chromocell Therapeutics Announces Closing ofÂ Initial Public Offering for Gross Proceeds of $6.6 Million(Yahoo Finance)
2024-02-15 19:00
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering(Yahoo Finance)

Page 1 of 1

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.